Technical Analysis for MREO - Mereo BioPharma Group plc

Grade Last Price % Change Price Change
D 3.09 -0.64% -0.02
MREO closed down 0.64 percent on Monday, March 18, 2024, on 42 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Mar 26
*** please verify all earnings dates ***
6 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Down

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Gapped Down Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Lower Bollinger Band Walk Weakness -0.64%
Below Lower BB Weakness -0.64%
Down 3 Days in a Row Weakness -0.64%

   Recent Intraday Alerts

Alert Time
Rose Above Previous Day's High about 12 hours ago
Gap Down Closed about 14 hours ago
Reversed from Down about 14 hours ago
60 Minute Opening Range Breakout about 14 hours ago
Rose Above Lower Bollinger Band about 17 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Mereo is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare diseases. Mereo's strategy is to selectively acquire product candidates that have substantial preclinical, clinical and manufacturing data packages. Mereo's four product candidates have previously generated positive clinical data for Mereo's target indications or in related indications. Mereo has commenced randomized Phase 2 clinical trials for all four of the product candidates. In connection with the merger with OncoMed, Mereo added two candidates to its pipeline, Navicixizumab and Etigilimab.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Rare Diseases Drug Discovery Clinical Research Clinical Trial Compugen

Is MREO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.36
52 Week Low 0.688
Average Volume 1,950,756
200-Day Moving Average 2.06
50-Day Moving Average 3.50
20-Day Moving Average 3.57
10-Day Moving Average 3.43
Average True Range 0.24
RSI (14) 33.33
ADX 31.4
+DI 12.25
-DI 23.90
Chandelier Exit (Long, 3 ATRs) 3.35
Chandelier Exit (Short, 3 ATRs) 3.66
Upper Bollinger Bands 4.08
Lower Bollinger Band 3.07
Percent B (%b) 0.02
BandWidth 28.32
MACD Line -0.10
MACD Signal Line 0.00
MACD Histogram -0.0954
Fundamentals Value
Market Cap 433.35 Million
Num Shares 140 Million
EPS -0.32
Price-to-Earnings (P/E) Ratio -9.66
Price-to-Sales 79.09
Price-to-Book 7.70
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.31
Resistance 3 (R3) 3.30 3.22 3.27
Resistance 2 (R2) 3.22 3.16 3.22 3.26
Resistance 1 (R1) 3.15 3.13 3.19 3.16 3.25
Pivot Point 3.07 3.07 3.09 3.08 3.07
Support 1 (S1) 3.01 3.02 3.04 3.02 2.93
Support 2 (S2) 2.93 2.98 2.93 2.92
Support 3 (S3) 2.86 2.93 2.91
Support 4 (S4) 2.87